Vimarsana
Biggest News Aggregation in the World

Shows Return News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Shows Return. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Shows Return Today - Breaking & Trending Today

GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) - Vimarsana News

GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)

In March 2023, Appropriate Use Criteria (AUC) for ER-targeted PET imaging was also published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI)

GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) - Vimarsana News

GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

NCCN Guidelines® for clinicians and patients now recommend the use of FES PET for ER+ positive disease under certain circumstances during the systemic staging workup of patients with recurrent... | May 24, 2023

Live Shows Return to Another Disneyland Theater - Vimarsana News

Live Shows Return to Another Disneyland Theater

Live shows have returned to another Disneyland theater with the return of Mr. Smyth and Mr. Jones to Fantasyland's Royal Theatre.

GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to Enable More Targeted Treatment for Metastatic Breast Cancer Patients - Vimarsana News

GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to Enable More Targeted Treatment for Metastatic Breast Cancer Patients

(1) GE Healthcare to scale Zionexa's FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S. by 2023 Acquisition demonstrates GE Healthcare's commitment to its precision health vision and builds additional pipeline of oncology and neurology tracers to help physicians personalize treatment GE Healthcare today announced ...

MIL-OSI Economics: GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to Enable More Targeted Treatment for Metastatic Breast Cancer Patients - Vimarsana News

MIL-OSI Economics: GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to Enable More Targeted Treatment for Metastatic Breast Cancer Patients

GE Healthcare to scale Zionexa’s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S. by 2023 Acquisition demonstrates GE Healthcare’s commitment to its precision health vision and builds additional pipeline of oncology and neurology tracers to help physicians personalize treatment 6 May 2021 – GE Healthcare to...